Institution
New York University
Education•New York, New York, United States•
About: New York University is a education organization based out in New York, New York, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 72380 authors who have published 165545 publications receiving 8334030 citations. The organization is also known as: NYU & University of the City of New York.
Topics: Population, Poison control, Context (language use), Health care, Cancer
Papers published on a yearly basis
Papers
More filters
••
University of Bonn1, German Center for Neurodegenerative Diseases2, Harvard University3, Maastricht University4, Aix-Marseille University5, Pierre-and-Marie-Curie University6, French Institute of Health and Medical Research7, University of Melbourne8, VU University Amsterdam9, New York University10, Mayo Clinic11, City University of New York12, University of New South Wales13, Indiana University14, King's College London15, University of Toulouse16
TL;DR: Research criteria for SCD in pre‐mild cognitive impairment (MCI) are presented and a list of core features proposed for reporting in SCD studies is provided, which will enable comparability of research across different settings.
Abstract: There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). The research on SCD in early AD, however, is limited by the absence of common standards. The working group of the Subjective Cognitive Decline Initiative (SCD-I) addressed this deficiency by reaching consensus on terminology and on a conceptual framework for research on SCD in AD. In this publication, research criteria for SCD in pre-mild cognitive impairment (MCI) are presented. In addition, a list of core features proposed for reporting in SCD studies is provided, which will enable comparability of research across different settings. Finally, a set of features is presented, which in accordance with current knowledge, increases the likelihood of the presence of preclinical AD in individuals with SCD. This list is referred to as SCD plus.
1,626 citations
••
University of Nottingham1, University of Edinburgh2, Case Western Reserve University3, New York University4, University of California, Los Angeles5, Southampton General Hospital6, Erasmus University Rotterdam7, Keele University8, University of Paris9, University of Maryland, Baltimore10, University of Sydney11, University of Pittsburgh12, Lund University13, University of Ottawa14
TL;DR: In this paper, a systematic literature search was undertaken using MEDLINE, EMBASE, CINAHL, AMED, Science Citation Index and the Cochrane Library to examine whether research evidence has changed from 31 January 2006 to 31 January 2009.
1,624 citations
••
Christopher P. Ahn1, Rachael Alexandroff2, Carlos Allende Prieto3, Scott F. Anderson4 +256 more•Institutions (65)
TL;DR: In this paper, the authors presented the first spectroscopic data from the Baryon Oscillation Spectroscopic Survey (BOSS) for the Sloan Digital Sky Survey III (SDSS-III) dataset.
Abstract: The Sloan Digital Sky Survey III (SDSS-III) presents the first spectroscopic data from the Baryon Oscillation Spectroscopic Survey (BOSS). This ninth data release (DR9) of the SDSS project includes 535,995 new galaxy spectra (median z ~ 0.52), 102,100 new quasar spectra (median z ~ 2.32), and 90,897 new stellar spectra, along with the data presented in previous data releases. These spectra were obtained with the new BOSS spectrograph and were taken between 2009 December and 2011 July. In addition, the stellar parameters pipeline, which determines radial velocities, surface temperatures, surface gravities, and metallicities of stars, has been updated and refined with improvements in temperature estimates for stars with T eff -0.5. DR9 includes new stellar parameters for all stars presented in DR8, including stars from SDSS-I and II, as well as those observed as part of the SEGUE-2. The astrometry error introduced in the DR8 imaging catalogs has been corrected in the DR9 data products. The next data release for SDSS-III will be in Summer 2013, which will present the first data from the APOGEE along with another year of data from BOSS, followed by the final SDSS-III data release in 2014 December.
1,623 citations
••
TL;DR: In this article, the authors derived the shear viscosity of the finite-temperature N = 4 supersymmetric Yang-Mills theory in the large N, strong-coupling regime with the absorption cross section of low-energy gravitons by a near-extremal black three-brane.
Abstract: Using the anti–de Sitter/conformal field theory correspondence, we relate the shear viscosity ? of the finite-temperature N = 4 supersymmetric Yang-Mills theory in the large N, strong-coupling regime with the absorption cross section of low-energy gravitons by a near-extremal black three-brane. We show that in the limit of zero frequency this cross section coincides with the area of the horizon. From this result we find ? = ? / 8N2T3. We conjecture that for finite ’t Hooft coupling gYM2N the shear viscosity is ? = f(gYM2N)N2T3, where f(x) is a monotonic function that decreases from O(x-2ln-1(1/x)) at small x to ?/8 when x??.
1,621 citations
••
TL;DR: Losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with Marfan syndrome and has the potential to prevent the major life-threatening manifestation of this disorder.
Abstract: Aortic aneurysm and dissection are manifestations of Marfan syndrome (MFS), a disorder caused by mutations in the gene that encodes fibrillin-1. Selected manifestations of MFS reflect excessive signaling by the transforming growth factor–β (TGF-β) family of cytokines. We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-β signaling and can be prevented by TGF-β antagonists such as TGF-β–neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation. These data suggest that losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with MFS and has the potential to prevent the major life-threatening manifestation of this disorder.
1,620 citations
Authors
Showing all 73237 results
Name | H-index | Papers | Citations |
---|---|---|---|
Rob Knight | 201 | 1061 | 253207 |
Virginia M.-Y. Lee | 194 | 993 | 148820 |
Frank E. Speizer | 193 | 636 | 135891 |
Stephen V. Faraone | 188 | 1427 | 140298 |
Eric R. Kandel | 184 | 603 | 113560 |
Andrei Shleifer | 171 | 514 | 271880 |
Eliezer Masliah | 170 | 982 | 127818 |
Roderick T. Bronson | 169 | 679 | 107702 |
Timothy A. Springer | 167 | 669 | 122421 |
Alvaro Pascual-Leone | 165 | 969 | 98251 |
Nora D. Volkow | 165 | 958 | 107463 |
Dennis R. Burton | 164 | 683 | 90959 |
Charles N. Serhan | 158 | 728 | 84810 |
Giacomo Bruno | 158 | 1687 | 124368 |
Tomas Hökfelt | 158 | 1033 | 95979 |